122 related articles for article (PubMed ID: 30539842)
1. Norcantharidin combined with diamminedichloroplatinum inhibits tumor growth and cancerometastasis of hepatic carcinoma in murine.
Zhang XP; Luo LL; Liu YQ; Liu XS; An FY; Sun SB; Xie XR; Geng GQ; Chen XJ; Li ZD
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1035-S1040. PubMed ID: 30539842
[TBL] [Abstract][Full Text] [Related]
2. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Ren J; Li G; Zhao W; Lin L; Ye T
World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
[TBL] [Abstract][Full Text] [Related]
3. Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells.
Liang L; Zhao L; Wang Y; Wang Y
Mol Pharm; 2021 Mar; 18(3):1003-1013. PubMed ID: 33527831
[TBL] [Abstract][Full Text] [Related]
4. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
5. Norcantharidin combined with Coix seed oil synergistically induces apoptosis and inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation.
Wang D; Yang C; Wang Z; Yang Y; Li D; Ding X; Xu W; Zheng Q
Sci Rep; 2017 Aug; 7(1):9373. PubMed ID: 28839202
[TBL] [Abstract][Full Text] [Related]
6. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin.
Xie MH; Ge M; Peng JB; Jiang XR; Wang DS; Ji LQ; Ying Y; Wang Z
Pharm Dev Technol; 2019 Jun; 24(5):623-629. PubMed ID: 30457414
[TBL] [Abstract][Full Text] [Related]
7. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
Jiang S; Li M; Hu Y; Zhang Z; Lv H
Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
[TBL] [Abstract][Full Text] [Related]
9. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.
Zhang JT; Sun W; Zhang WZ; Ge CY; Liu ZY; Zhao ZM; Lu XS; Fan YZ
BMC Cancer; 2014 Mar; 14():193. PubMed ID: 24628713
[TBL] [Abstract][Full Text] [Related]
10. [Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms].
Fan YZ; Chen CQ; Zhao ZM; Sun W
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):693-9. PubMed ID: 16681930
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.
Fan YZ; Zhao ZM; Fu JY; Chen CQ; Sun W
Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):414-22. PubMed ID: 20688607
[TBL] [Abstract][Full Text] [Related]
12. Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity.
Yeh CB; Hsieh MJ; Hsieh YH; Chien MH; Chiou HL; Yang SF
PLoS One; 2012; 7(2):e31055. PubMed ID: 22363545
[TBL] [Abstract][Full Text] [Related]
13. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.
Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B
Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802
[TBL] [Abstract][Full Text] [Related]
14. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect.
Chen YJ; Tsai YM; Kuo CD; Ku KL; Shie HS; Liao HF
Life Sci; 2009 Oct; 85(17-18):642-51. PubMed ID: 19765597
[TBL] [Abstract][Full Text] [Related]
15. Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma.
Ahn CH; Hong KO; Jin B; Lee W; Jung YC; Lee H; Shin JA; Cho SD; Hong SD
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31315217
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effect of norcantharidin combined with evodiamine on the growth of human hepatic carcinoma cell line HepG2 in vitro].
Liu Y; Zahng J; You Z; Liao H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):824-8. PubMed ID: 25108435
[TBL] [Abstract][Full Text] [Related]
17. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
Jin D; Wu Y; Shao C; Gao Y; Wang D; Guo J
Oncol Rep; 2018 Aug; 40(2):609-620. PubMed ID: 29901163
[TBL] [Abstract][Full Text] [Related]
18. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
19. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
20. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy.
Guan M; Zhou Y; Zhu QL; Liu Y; Bei YY; Zhang XN; Zhang Q
Nanomedicine; 2012 Oct; 8(7):1172-81. PubMed ID: 22321383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
